

1. Project Title

Fixed Capital Outlay

**Total State Funds Requested** 

## The Florida Senate Local Funding Initiative Request Fiscal Year 2021-2022

Office of the State Courts Administrator (OSCA) Vivitrol Program

LFIR # 1185

847,408

2. Senate Sponsor	Ana Maria Rodriguez				
3. Date of Request	01/25/2021				
4. Project/Program De	escription				
and the Centers for large practice approach to treatment providers injectable naltrexone	Disease Control (CDC) strong serve individuals with alcoording for provision of substance	ongly advoca ohol and opic abuse scree tions for indiv	Administration (SAMHSA), late for the use of medication bid use disorders. The requening, medical assessments/viduals with alcohol and/or our involvement.	-assisted treat sted program lab work and e	ment as a best funds community extended-release
5. State Agency to red	ceive requested funds	State Cou	rt System		
State Agency conta	cted? Yes				
6. Amount of the Nonr	ecurring Request for Fis	scal Year 202	21-2022		
Type of Funding			Amount		
Operations				847,408	

7. Total Project Cost for Fiscal Year 2021-2022 (including matching funds available for this project)

Type of Funding	Amount	Percentage
Total State Funds Requested (from question #6)	847,408	14%
Matching Funds		
Federal	0	0%
State (excluding the amount of this request)	5,000,000	86%
Local	0	0%
Other	0	0%
Total Project Costs for Fiscal Year 2021-2022	5,847,408	100%

8. Has this project previously received state funding?

Fiscal Year	Amo	ount	Specific	Vetoed	
(уууу-уу)	Recurring	Nonrecurring	Appropriation #		
2020-21	5,000,000	500,000	3229	No	

9. Is future funding likely to be requested?	Yes				
a. If yes, indicate nonrecurring amount per year.	500,000				
b. Describe the source of funding that can be used in lieu of state funding.					
We are not aware of other funding sources					

10. Has the entity requesting this project received any federal assistance related to the COVID-19 pandemic?

No
----

Yes



### The Florida Senate Local Funding Initiative Request Fiscal Year 2021-2022

LFIR # 1185

If yes, indicate the amount of funds received and what the funds were used for.				

### 11. Details on how the requested state funds will be expended

Spending Category	gory Description		
Administrative Costs:			
Executive Director/Project Head Salary and Benefits		0	
Other Salary and Benefits		0	
Expense/Equipment/Travel/Supplies/ Other		0	
Consultants/Contracted Services/Study	Payment to community-based treatment providers for provision of screening, medical assessment, and extended-release naltrexone injections for alcohol and/or opioid dependent individuals that are court-involved or at-risk for court involvement.	847,408	
Operational Costs: Other			
Salary and Benefits		0	
Expense/Equipment/Travel/Supplies/ Other		0	
Consultants/Contracted Services/Study		0	
Fixed Capital Construction/Majo	r Renovation:		
Construction/Renovation/Land/ Planning Engineering		0	
Total State Funds Requested (m	ust equal total from question #6)	847,408	

### 12. Program Performance

a. What specific purpose or goal will be achieved by the funds requested?

In response to the opioid epidemic and the increasing problem of alcohol abuse/dependence among Florida's citizens due to the COVID-19 pandemic, the program facilitates recovery from substance abuse, lower rates of opioid overdose, and reduced costs to society for employment issues, high-cost healthcare utilization, and court involvement related to substance misuse, abuse, and dependence.

b. What activities and services will be provided to meet the intended purpose of these funds?

Program funds substance abuse screening/evaluation, medical assessment, and extended-release injectable naltrexone medication to help individuals with opioid and/or alcohol dependence achieve recovery through enhanced retention/completion rates for outpatient, residential, and other forms of psychosocial treatment.

c. What direct services will be provided to citizens by the appropriation project?

Substance abuse screenings, medical assessments, and administration of extended-release injectable naltrexone medication.

d. Who is the target population served by this project? How many individuals are expected to be served?

The requested funds, in conjunction with other state funds enable the program to serve 2,038 patients who are court-involved or at-risk for court involvement and present with alcohol and/or opioid abuse and dependence problems. The requested funds would support screening, medical assessment/lab work, and extended-release injectable naltrexone medication for 185 of the total 2,038 patients.

e. What is the expected benefit or outcome of this project? What is the methodology by which this outcome will be measured?



### The Florida Senate Local Funding Initiative Request Fiscal Year 2021-2022

LFIR # 1185

The use of medication in substance abuse treatment supports improved retention in traditional treatment. At least 58% of individuals receiving extended-release injectable naltrexone services will successfully complete or remain actively engaged in psychosocial treatment for addiction problems with alcohol and/or opioids at time of discharge from medication-assisted treatment (MAT) services. Algorithm includes all individuals successfully completing or still actively engaged in psychosocial treatment at time of discharge from services divided by all individuals discharged from MAT services.

f. What are the suggested penalties that the contracting agency may consider in addition to its standard penalties for failing to meet deliverables or performance measures provided for the contract?

The program has operated well throughout its 6-year history - current penalties in the contract for failure to meet deliverables or performance measures are sufficient.

13. The owners of the facility to receive, directly or indirectly, any fixed capital outlay funding, include the

relationship between the owners of the facility and the entity.			

N/A		
IN/ / \		



# The Florida Senate Local Funding Initiative Request Fiscal Year 2021-2022

LFIR # 1185

14.	Requestor Contact	Informat	ion				
	a. First Name	Darran		Last Name	Duchene		
	b. Organization	Florida Alcohol and Drug Abuse Association					
	c. E-mail Address	darran@f	darran@floridabha.org				
	d. Phone Number	(850)878	-2196	Ext.			
15.	Recipient Contact	Informatio	on				
	a. Organization	Florida Al (FADAA)	cohol and Drug	Abuse Assoc	iation		
	b. Municipality and	l County	Statewide				
	c. Organization Ty	ре					
	□For Profit Entity						
	☑Non Profit 501(c	c)(3)					
	□Non Profit 501(c	s)(4)					
	□Local Entity						
	□University or Co	llege					
	□Other (please sp	ecify)					
	d. First Name	Darran		Last Name	Duchene		
	e. E-mail Address	darran@f	loridabha.org				
	f. Phone Number	(850)878-2196					
16.	16. Lobbyist Contact Information						
	a. Name	Frank P., Jr. Mayernick					
	b. Firm Name	The May	ernick Group LL0	2			
	c. E-mail Address	frank@themayernickgroup.com					
	d. Phone Number	(850)251-8898					